Yield10 Bioscience, Inc. Common Stock
YTEN
YTEN was delisted on the 15th of May, 2024.
15 hedge funds and large institutions have $206K invested in Yield10 Bioscience, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 3 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
25% more funds holding
Funds holding: 12 → 15 (+3)
86% less capital invested
Capital invested by funds: $1.51M → $206K (-$1.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$57.9K |
| 2 |
CCB
Cutter & Co Brokerage
Ballwin,
Missouri
|
+$52.4K |
| 3 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$43K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$29K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$27.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$480K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$69.7K |
| 3 |
CWP
Concord Wealth Partners
Abingdon,
Virginia
|
-$7.77K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.12K |
YTEN Hedge Fund Activity: Q3 2023 in Review
15 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Yield10 Bioscience, Inc. Common Stock (YTEN) for Q3 2023, worth a combined $206K — down 86% from $1.51M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new YTEN positions and 3 closed out — a net gain of 4 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $57.9K. The largest seller was Armistice Capital, exiting entirely with an estimated $480K sold.
- 15 institutional investors held Yield10 Bioscience, Inc. Common Stock (YTEN) as of Q3 2023, up from 12 in Q2 2023.
- Funds reported $206K of Yield10 Bioscience, Inc. Common Stock stock for Q3 2023, down 86% quarter-over-quarter.
- 7 funds opened new Yield10 Bioscience, Inc. Common Stock positions in Q3 2023 and 3 closed out, a net change of +4 holders.
- The largest Yield10 Bioscience, Inc. Common Stock buyer in Q3 2023 was Millennium Management, an estimated $57.9K added.
- The largest Yield10 Bioscience, Inc. Common Stock seller in Q3 2023 was Armistice Capital, an estimated $480K sold.
Based on aggregated 13F filings for Q3 2023.